NASDAQ · Financial Statements

Clearside Biomedical, Inc. (CLSD) Financial Statements

$0.41 NASDAQ: CLSD Market Cap $2.15M

Clearside Biomedical, Inc. most recently reported annual revenue of $2.0M, a net loss of $34.0M. Revenue was roughly flat over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Clearside Biomedical, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -4845.8% to -1735.7%, a shift of +3110.1 percentage points; the most recent year shows a net loss of $34.0M.

Income Statement — 10 Years (USD millions)

Metric2015201620172018201920202021202220232024
Revenue$0$1.0M$0$0$2.0M$8.0M$30.0M$1.0M$8.0M$2.0M
Operating Expenses$17.0M$26.0M$59.0M$83.0M$32.0M$26.0M$30.0M$32.0M$33.0M$31.0M
Operating Profit$-17.0M$-25.0M$-58.0M$-83.0M$-30.0M$-18.0M$-1.0M$-30.0M$-25.0M$-29.0M
Operating Margin0.0%-4845.8%-16929.9%-276483.3%-1394.6%-227.2%-2.1%-2281.6%-302.0%-1735.7%
Other Income$0$-1.0M$-1.0M$0$0$0$1.0M$-3.0M$-8.0M$-5.0M
Interest$0$0$0$0$1.0M$0$0$3.0M$9.0M$10.0M
Depreciation$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-18.0M$-26.0M$-59.0M$-83.0M$-31.0M$-18.0M$0$-33.0M$-32.0M$-34.0M
Tax$-50,000$250,000$310,000$-150,000$0$0$0$0$0$0
Net Profit$-18.0M$-26.0M$-59.0M$-83.0M$-31.0M$-18.0M$0$-33.0M$-32.0M$-34.0M
EPS$-21.60$-29.55$-34.95$-40.35$-12.00$-5.85$0.09$-8.25$-7.95$-7.05
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '22Mar '23Jun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25
Revenue$0$0$1.0M$1.0M$6.0M$0$0$1.0M$0$2.0M$0$0
Operating Expenses$8.0M$8.0M$8.0M$8.0M$9.0M$8.0M$8.0M$7.0M$7.0M$8.0M$4.0M$7.0M
Operating Profit$-8.0M$-8.0M$-7.0M$-7.0M$-3.0M$-8.0M$-8.0M$-6.0M$-7.0M$-5.0M$-4.0M$-7.0M
Operating Margin-2445.4%-190125.0%-714.1%-821.2%-45.9%-3569.1%-8433.3%-571.7%-2336.3%-223.4%-725.2%-3502.5%
Interest$2.0M$2.0M$2.0M$3.0M$2.0M$2.0M$2.0M$2.0M$3.0M$3.0M$3.0M$3.0M
Profit Before Tax$-10.0M$-9.0M$-9.0M$-9.0M$-5.0M$-12.0M$-8.0M$-8.0M$-7.0M$-8.0M$-4.0M$-6.0M
Tax$0$0$0$0$0$0$0$0$0$-9.5M$0$0
Net Profit$-10.0M$-9.0M$-9.0M$-9.0M$-5.0M$-12.0M$-8.0M$-8.0M$-7.0M$-8.0M$-4.0M$-6.0M
EPS$-2.10$-2.25$-2.25$-2.25$-1.16$-2.55$-1.50$-1.50$-1.44$-1.65$-0.87$-1.14

Over the 10 years reported for Clearside Biomedical, Inc., borrowings increased from $6.0M in 2015 to $52.0M in 2024, cash stood at $20.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.20 times.

Balance Sheet — 10 Years (USD millions)

Metric2015201620172018201920202021202220232024
Total Assets$21.0M$85.0M$40.0M$44.0M$27.0M$19.0M$43.0M$51.0M$34.0M$25.0M
Current Assets$20.0M$84.0M$38.0M$43.0M$25.0M$18.0M$42.0M$49.0M$30.0M$21.0M
Cash$20.0M$35.0M$9.0M$8.0M$23.0M$17.0M$30.0M$48.0M$29.0M$20.0M
Inventory$0$0$0$0$0$0$1.0M$0$0$0
Receivables$0$0$0$0$0$0$10.0M$0$0$1.0M
Fixed Assets$0$0$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M$4.0M$4.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$49.0M$29.0M$33.0M$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$58.0M$13.0M$19.0M$21.0M$16.0M$11.0M$5.0M$41.0M$50.0M$64.0M
Current Liabilities$5.0M$5.0M$14.0M$10.0M$11.0M$10.0M$5.0M$6.0M$7.0M$5.0M
Borrowings$6.0M$8.0M$8.0M$10.0M$6.0M$2.0M$1.0M$35.0M$43.0M$52.0M
Other Liabilities$52.0M$6.0M$11.0M$11.0M$9.0M$9.0M$4.0M$5.0M$7.0M$12.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$-37.0M$72.0M$21.0M$24.0M$11.0M$9.0M$38.0M$11.0M$-16.0M$-39.0M

For Clearside Biomedical, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $26.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2015201620172018201920202021202220232024
Operating Cash Flow$-14.0M$-23.0M$-51.0M$-79.0M$-27.0M$-13.0M$-11.0M$-13.0M$-18.0M$-25.0M
Investing Cash Flow$0$-49.0M$20.0M$-4.0M$33.0M$0$0$0$-4.0M$-2.0M
Financing Cash Flow$0$0$0$1.0M$0$0$0$0$-1.0M$0
Net Cash Flow$12.0M$15.0M$-26.0M$-1.0M$15.0M$-5.0M$13.0M$18.0M$-19.0M$-9.0M
Free Cash Flow$-14.0M$-23.0M$-51.0M$-79.0M$-27.0M$-13.0M$-11.0M$-14.0M$-20.0M$-26.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.43
FCF Yield-747.41%
Quick Ratio2.98
Interest Coverage-1.98
Return 1Y—
Return 3Y—
Return 5Y—

Clearside Biomedical, Inc. (CLSD) financials — frequently asked questions

What is Clearside Biomedical, Inc.'s annual revenue?

Clearside Biomedical, Inc. (CLSD) reported annual revenue of $2.0M in its most recent fiscal year.

What is Clearside Biomedical, Inc.'s net profit?

Clearside Biomedical, Inc. (CLSD) reported a net loss of $34.0M in its most recent fiscal year.

What is CLSD EV/EBITDA?

Clearside Biomedical, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.43.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
CLSD Overview CLSD Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.